Details of the Drug Combinations

General Information of This Drug (ID: DME4LA1)

Drug Name

Tideglusib DME4LA1

Synonyms

NP-031112; NP-12; NP031112; Tideglusib(NP-031112)

Indication

Disease Entry	ICD 11	Status	REF
Alzheimer disease	8A20	Phase 2	[1]
Osteosarcoma	2B51	Phase 2	[2]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Investigative	[3]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Tideglusib + Idarubicin	DCU8EJL	Idarubicin	Glioblastoma? (Cell Line: T98G)	[4]
------------------------------------------------------------------------------------

References

1	A Phase II Trial of Tideglusib in Alzheimer's Disease. J Alzheimers Dis. 2015;45(1):75-88.
2	Evidence for irreversible inhibition of glycogen synthase kinase-3beta by tideglusib. J Biol Chem. 2012 Jan 6;287(2):893-904.
3	Structure of Mpro from COVID-19 virus and discovery of its inhibitors. Nature. 2020 Apr 9.
4	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.